Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2024
Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: A single-center case series.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Handa Takaya, Fujii Masaki, Ando Masumi, Masuda Mayumi, Sokai Yuko, Tsuji Yoshiki, Fukuda Yui, Ohue Kaoru, Higashi Yoshiaki, Mori Keita P, Endo Tomomi, Tsukamoto Tatsuo
Аннотация
INTRODUCTION: A novel LDL (low-density lipoprotein) apheresis therapeutic option, Rheocarna, has garnered attention as an alternative therapy for chronic limb-threating ischemia (CLTI). Bradykinin-mediated vasodilation is involved in the effects of LDL apheresis and a decrease in blood pressure (BP), but the changes in bradykinin concentration during Rheocarna therapy are unknown.
METHODS: The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.
RESULTS: After Rheocarna therapy, skin ulcers improved in 80% of the patients. Circuit coagulation was observed in two patients with high fibrinogen levels. A decrease in BP was observed at approximately the same time when the bradykinin concentration peaked. The peak bradykinin concentration in a patient undergoing hemodialysis at the same time was considerably lower than that in the other patients.
CONCLUSION: This is the first report on the changes in bradykinin concentration under Rheocarna therapy.
METHODS: The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.
RESULTS: After Rheocarna therapy, skin ulcers improved in 80% of the patients. Circuit coagulation was observed in two patients with high fibrinogen levels. A decrease in BP was observed at approximately the same time when the bradykinin concentration peaked. The peak bradykinin concentration in a patient undergoing hemodialysis at the same time was considerably lower than that in the other patients.
CONCLUSION: This is the first report on the changes in bradykinin concentration under Rheocarna therapy.